Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Autor: Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Publikováno v: Ann Transl Med
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f1362cea0664cfe2470bd04f49b410
https://hdl.handle.net/2318/1742132

Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancer

Autor: Copur, M.Sitki, Ledakis, P, Lynch, J, Hauke, R, Tarantolo, S, Bolton, M, Norvell, M, Muhvic, J, Hake, L, Wendt, J

Publikováno v: In Seminars in Oncology 2001 28 Supplement 15:16-21

S129: TAKEAIM LEUKEMIA‐ A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA‐4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS.

Autor: Garcia‐Manero, G., Winer, E. S., DeAngelo, D. J., Tarantolo, S., Sallman, D. A., Dugan, J., Groepper, S., Giagounidis, A., Götze, K., Metzeler, K. H., Li, C.‐C., Zhou, L., Martinez, E., Lane, M., von Roemeling, R., Bohme, M., Kubasch, A. S., Verma, A., Platzbecker, U.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p30-31, 2p

Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis

Autor: Martin-Algarra S, Bishop MR, Tarantolo S, Mk, Cowles, Reed E, Jr, Anderson, Jm, Vose, Bierman P, Jo, Armitage, Kessinger A

Publikováno v: Europe PubMed Central

The use of hematopoietic growth factors (HGFs) in the allogeneic transplant setting has sometimes been avoided for fear of stimulating leukemic cell growth and intensifying graft-vs.-host disease (GVHD). However, neither an increase in relapse rate n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5d5a6e000544407bbefc29f478b6dd0e
https://pubmed.ncbi.nlm.nih.gov/8542938

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.